8,735 reports of this reaction
11.7% of all PIOGLITAZONE reports
#1 most reported adverse reaction
BLADDER CANCER is the #1 most commonly reported adverse reaction for PIOGLITAZONE, manufactured by Takeda Pharmaceuticals America, Inc.. There are 8,735 FDA adverse event reports linking PIOGLITAZONE to BLADDER CANCER. This represents approximately 11.7% of all 74,368 adverse event reports for this drug.
PIOGLITAZONE has an overall safety score of 85 out of 100. Patients taking PIOGLITAZONE who experience bladder cancer should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLADDER CANCER is a frequently reported adverse event for PIOGLITAZONE, accounting for a significant proportion of all reports.
In addition to bladder cancer, the following adverse reactions have been reported for PIOGLITAZONE:
The following drugs have also been linked to bladder cancer in FDA adverse event reports:
BLADDER CANCER has been reported as an adverse event in 8,735 FDA reports for PIOGLITAZONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLADDER CANCER accounts for approximately 11.7% of all adverse event reports for PIOGLITAZONE, making it one of the most commonly reported side effect.
If you experience bladder cancer while taking PIOGLITAZONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.